Palatin Technologies (PTN)
XASE:PTN
Want to see PTN full AI Analyst Report?
PTN Stock Chart & Stats
$16.05
--
Market closed
$16.05
--
Day’s Range― - ―
52-Week Range$4.50 - $31.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.99K
Market Cap
$26.56M
Enterprise Value$492.21M
Total Cash (Recent Filing)$10.16M
Total Debt (Recent Filing)$286.66K
Price to Earnings (P/E)―
Beta-0.26
Next Earnings
Nov 16, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.56
Shares Outstanding1,779,275
10 Day Avg. Volume2,746
30 Day Avg. Volume2,993
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.18
Enterprise Value/Market Cap18.53
Enterprise Value/Revenue54.91
Enterprise Value/Gross Profit55.33
Enterprise Value/Ebitda-77.04
Forecast
1Y Price Target
$47.50Price Target Upside195.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-4.24
Revenue Forecast (FY)$11.09M
Bulls Say, Bears Say
Bulls Say
Partnership-driven Non-dilutive FundingMaterial upfront and milestone payments from partners provide non-dilutive capital and validate Palatin's programs. Such deals reduce immediate equity financing need, extend runway when realized, and create durable optionality via future milestones and royalties tied to partnered commercialization.
Low Financial LeverageVery modest debt levels lower solvency risk and preserve flexibility for strategic partnering or selective financing. Low leverage reduces near-term fixed obligations, giving management optionality to time capital raises, prioritize R&D spend, and navigate clinical timelines without heavy interest burdens.
Peptide MC4R Program Progressing To INDA clear regulatory timeline toward an IND represents structural de-risking: advancing IND-enabling studies and planned submission crystallize development milestones, improving partnerability and future revenue potential if clinical data validate tolerability and efficacy over the long term.
Bears Say
Sustained Negative Cash GenerationPersistent, sizable cash burn signals ongoing dependence on external funding and constrains the firm's ability to internally finance development. Over months, this increases dilution risk, limits strategic flexibility to pursue multiple programs, and pressures management to secure timely partner or financing deals.
Limited Cash RunwayA projected runway only to mid-2027 creates a near-term funding cliff that can force rushed financings or dependence on milestone timing. This constrains multi-year trial planning, elevates execution risk, and may necessitate dilutive capital or accelerated partnering under less favorable terms.
Competitive And Timing DisadvantageBeing years behind an approved MC4R therapy reduces potential market share and bargaining leverage for pricing or partnerships. Delays in the oral program and deprioritization of earlier assets increase risk that Palatin's candidates miss key market windows, limiting long-term commercial upside.
Palatin Technologies News
PTN FAQ
What was Palatin Technologies’s price range in the past 12 months?
Palatin Technologies lowest stock price was $4.50 and its highest was $31.00 in the past 12 months.
What is Palatin Technologies’s market cap?
Palatin Technologies’s market cap is $26.56M.
When is Palatin Technologies’s upcoming earnings report date?
Palatin Technologies’s upcoming earnings report date is Nov 16, 2026 which is in 185 days.
How were Palatin Technologies’s earnings last quarter?
Palatin Technologies released its earnings results on May 13, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$1.243 by $0.873.
Is Palatin Technologies overvalued?
According to Wall Street analysts Palatin Technologies’s price is currently Undervalued.
Does Palatin Technologies pay dividends?
Palatin Technologies does not currently pay dividends.
What is Palatin Technologies’s EPS estimate?
Palatin Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Palatin Technologies have?
Palatin Technologies has 1,779,275 shares outstanding.
What happened to Palatin Technologies’s price movement after its last earnings report?
Palatin Technologies reported an EPS of -$0.37 in its last earnings report, beating expectations of -$1.243. Following the earnings report the stock price went down -16.011%.
Which hedge fund is a major shareholder of Palatin Technologies?
Currently, no hedge funds are holding shares in PTN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palatin Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$47.50 (195.95% Upside)
$47.50 (195.95% Upside)
Hedge Fund Trend
Increased
By 306.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-85.90%
12-Months-Change
Fundamentals
Return on Equity
-5515.09%
Trailing 12-Months
Asset Growth
315.95%
Trailing 12-Months
Company Description
Palatin Technologies
Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey.
PTN Earnings Call
Q3 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
Balanced: The call highlighted meaningful near-term commercial validation via upfront collaboration revenue, materially reduced net loss, reduced operating cash burn, strong partnership-driven non-dilutive funding and clear progress across peptide and oral MC4R programs (including IP development). Offsetting these positives are increased operating costs, a limited cash runway to mid-2027 that creates funding risk, a deprioritized earlier oral candidate and timing/competitive risks (notably Rhythm's approved product). Clinical risk around hyperpigmentation and the need for further IND/clinic-readout milestones keep the outlook cautious.View all PTN earnings summariesPTN Stock 12 Month Forecast
Average Price Target
$47.50
▲(195.95% Upside)
Technical Analysis
Ibio
―
Phio Pharmaceuticals
―
BioRestorative Therapies
―
Addex Therapeutics
―
Bolt Biotherapeutics
―
Ownership Overview
11.20% Insiders
1.97% Mutual Funds
0.72% Other Institutional Investors
85.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---